Dupixent [dupilumab injection for subcutaneous use] prescribing information. Regeneron Pharmaceuticals Inc., Tarrytown, NY; sanofi-aventis U.S. LLC, Bridgewater, NJ. June 2020. 7. Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-...
Globally, prescribing information varies; refer to the individual country product label for complete information. About AbbVie AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve...
Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761055s014lbl.pdf. Accessed 10 Dec 2022. Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N ...
During the past decade, significant therapeutic progress has been made in the field of allergic diseases, mainly concerning the pathogenic role of type 2 inflammation. Biologics targeting specific key cytokines, such as interleukin (IL)-4, IL-5, and IL-13, as well as IgE, have emerged as pr...
Highlights of prescribing information. US Food and Drug Administration. 2022. https://www.regeneron.com/sites/default/files/Dupixent_FPI.pdf. Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in ...
Highlights of prescribing information. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761055s014lbl.pdf. Revised June 2019. Accessed Nov 2020. Sanofi-Aventis Canada Inc. Dupixent. Public Health Agency of Canada.Summary Basis of Decision–...